

# AstraZeneca

## VT S.92 (Act 193, Sec.10.18 V.S.A. Â§ 4637) Reporting

### Overview

In Accordance with the requirements of subsection B set forth in the VT S.92 (Act 193, Sec.10.18 V.S.A. Â§ 4637) regulation, this is our 30-day post launch report of the introduction of the products listed below, into the state of Vermont.

### The Product(s)

SOLUTION 10MG/0.5ML 1X SYRINGE

### Marketing Plans

AstraZeneca provides online resources via Wainua US healthcare professionals (<https://www.fasenrahcp.com/>) and patient (<https://www.fasenra.com/>) websites.

### Pricing Plans

Branded Name	Generic Name	NDC	WAC Package Price	Effective Date
FASENRA	BENRALIZUMAB	00310-1745-01	\$1892.25	06/03/2024

When setting the price of medicines AstraZeneca aims to reflect its value to patients, to payers, and to society in general as well as the cost of research and development (R&D). AstraZeneca's pricing decisions are based on many factors that reflect our commitment to patients and the US Healthcare System as well as our obligation to shareholders. We are mindful of healthcare costs and are working to explore innovative opportunities and solutions working with others in the US Healthcare system to deliver innovative medicines while considering cost and value.

Importantly, the WAC or list price is rarely the price paid by an individual patient as it does not account for a series of factors, including individual insurance plan design, provider access, assistance programs or savings offers.

### Estimated Volume of Patients

The current estimated patient population per year is 249.

## **Breakthrough Designation**

N/A

## **Date of Acquisition**

The date of acquisition of the product(s) is listed below.

<b>NDC</b>	<b>Date of Acquisition</b>
00310-1745-01	N/A